Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993210priorityCriticalpatent/ECSP993210A/en
Publication of ECSP993210ApublicationCriticalpatent/ECSP993210A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a un preprado farmacéutico para la administarción oral que contiene moxifloxacina, una sal o hidrato de la misma asi como al uso de este preparado para combatir infecciones baterianas en seres humanos o animales.The present invention relates to a pharmaceutical preparation for oral administration containing moxifloxacin, a salt or hydrate thereof, as well as the use of this preparation to combat bacterial infections in humans or animals.
ECSP9932101999-11-091999-11-09
PHARMACEUTICAL PREPARATION FOR MOXIFLOXACIN (LEA 33327-EC)
ECSP993210A
(en)
5-AMINO-3- MALEATE SALT (2 ', 3'-DI-O-ACETYL-BETA-D-RIBOFURANOSIL) -3H-TIAZOLO [4,5-D] PIRIMIDIN-2-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF A PO INFECTION
a composition for the nasal delivery, use of granisetron or a pharmaceutically acceptable salt thereof, and chitosan, a salt, derivative or salt of a derivative thereof, methods of administration of granisetron or a pharmaceutically acceptable salt thereof, and nausea and / or vomiting treatment or prevention, and, nasal drug delivery device or a dose cartridge
Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases.